[go: up one dir, main page]

BRPI0515649B8 - Processo para preparação de composições de anticorpo monoclonal altamente concentradas - Google Patents

Processo para preparação de composições de anticorpo monoclonal altamente concentradas

Info

Publication number
BRPI0515649B8
BRPI0515649B8 BRPI0515649A BRPI0515649A BRPI0515649B8 BR PI0515649 B8 BRPI0515649 B8 BR PI0515649B8 BR PI0515649 A BRPI0515649 A BR PI0515649A BR PI0515649 A BRPI0515649 A BR PI0515649A BR PI0515649 B8 BRPI0515649 B8 BR PI0515649B8
Authority
BR
Brazil
Prior art keywords
highly concentrated
preparing highly
monoclonal antibody
antibody compositions
concentrated monoclonal
Prior art date
Application number
BRPI0515649A
Other languages
English (en)
Inventor
Matthew Winter Charles
Original Assignee
Genentech Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0515649(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Novartis Ag filed Critical Genentech Inc
Publication of BRPI0515649A publication Critical patent/BRPI0515649A/pt
Publication of BRPI0515649B1 publication Critical patent/BRPI0515649B1/pt
Publication of BRPI0515649B8 publication Critical patent/BRPI0515649B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)

Abstract

processo para preparação de composições de proteínas altamente concentradas. a presente invenção fornece um processo para concentrar proteínas incluindo ultrafiltração, diafiltração e uma segunda seqüência ultrafiltração, em temperaturas elevadas, tais como aproximadamente acima de 30°c. a presente invenção inclui também um processo para preparar composições altamente concentradas de anticorpo e produtos de anticorpo altamente concentrados.
BRPI0515649A 2004-09-09 2005-09-08 Processo para preparação de composições de anticorpo monoclonal altamente concentradas BRPI0515649B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US60/609,092 2004-09-09
US11/220,362 2005-09-06
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof
PCT/US2005/031844 WO2006031560A2 (en) 2004-09-09 2005-09-08 Process for concentration of antibodies and therapeutic products thereof

Publications (3)

Publication Number Publication Date
BRPI0515649A BRPI0515649A (pt) 2008-07-29
BRPI0515649B1 BRPI0515649B1 (pt) 2021-10-13
BRPI0515649B8 true BRPI0515649B8 (pt) 2021-11-03

Family

ID=35996499

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515649A BRPI0515649B8 (pt) 2004-09-09 2005-09-08 Processo para preparação de composições de anticorpo monoclonal altamente concentradas

Country Status (33)

Country Link
US (6) US20060051347A1 (pt)
EP (5) EP3805248B1 (pt)
JP (2) JP5210633B2 (pt)
KR (2) KR20070109975A (pt)
CN (3) CN101056885B (pt)
AR (1) AR050641A1 (pt)
AU (1) AU2005285243C1 (pt)
BR (1) BRPI0515649B8 (pt)
CA (1) CA2577317C (pt)
DK (5) DK4104859T3 (pt)
EC (1) ECSP077282A (pt)
ES (5) ES2528541T3 (pt)
FI (4) FI3805248T3 (pt)
GT (1) GT200500254A (pt)
HK (2) HK1101249A1 (pt)
HU (4) HUE065025T2 (pt)
IL (2) IL181372A (pt)
LT (4) LT4104859T (pt)
MA (1) MA28991B1 (pt)
MX (2) MX2007002812A (pt)
MY (2) MY162525A (pt)
NO (1) NO333660B1 (pt)
NZ (1) NZ553239A (pt)
PE (1) PE20060816A1 (pt)
PL (5) PL2292636T3 (pt)
PT (5) PT2292636T (pt)
RU (1) RU2390524C2 (pt)
SG (1) SG177161A1 (pt)
SI (5) SI2292636T1 (pt)
TN (1) TNSN07069A1 (pt)
TW (1) TWI372630B (pt)
WO (1) WO2006031560A2 (pt)
ZA (1) ZA200701626B (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
AU2005209360B2 (en) 2004-01-30 2009-06-25 Takeda Pharmaceutical Company Limited Production and purification of recombinant arylsulfatase A
MXPA06012989A (es) 2004-05-12 2007-06-12 Baxter Int Microesferas de acidos nucleicos, produccion y suministro de las mismas.
DE602005009954D1 (de) 2004-05-12 2008-11-06 Baxter Int Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
CN101415482B (zh) * 2006-03-31 2015-04-15 金克克国际有限公司 用于化合物分离的切向流动过滤设备、系统和方法
CA2882501C (en) * 2006-04-04 2021-09-07 Zymenex A/S Compositions comprising alpha mannosidase and uses thereof
WO2008121301A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human il-12 antibodies
KR101215740B1 (ko) 2007-07-17 2012-12-27 루드비히-막시밀리안스-우니버지테트 뮌헨 가변적 접선류 여과
JP5205470B2 (ja) * 2007-11-29 2013-06-05 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリン凝集物
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20210049186A (ko) * 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
ES2406029T3 (es) 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
DK2280999T3 (da) * 2008-05-15 2017-11-13 Biosys Health Inc Fremgangsmåde til fremstilling af mælkefraktioner, som er rige på sekretoriske immunglobuliner
US20110236391A1 (en) * 2008-12-09 2011-09-29 Hanns-Christian Mahler Method for obtaining an excipient-free antibody solution
WO2010090864A2 (en) * 2009-01-21 2010-08-12 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
CA2754528A1 (en) * 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation
JP6159528B2 (ja) * 2009-03-24 2017-07-05 ワイス・エルエルシー 高濃縮のタンパク質治療薬を生成するための膜蒸発
CA2763138A1 (en) * 2009-05-27 2010-12-02 Baxter International Inc. A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
CA2772846C (en) 2009-09-29 2020-09-29 F. Hoffmann-La Roche Ag Pre-filtration adjustment of buffer solutes
KR101718301B1 (ko) * 2009-10-01 2017-03-20 에프. 호프만-라 로슈 아게 다단계 최종 여과
ES2716088T3 (es) 2010-02-04 2019-06-10 Csl Behring Ag Preparado de inmunoglobulina
MY174760A (en) 2010-03-01 2020-05-13 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2729566B1 (en) 2011-07-08 2017-03-15 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
MX359235B (es) * 2011-09-01 2018-09-20 Chugai Pharmaceutical Co Ltd Metodo para preparar una composicion que comprende anticuerpos altamente concentrados por ultrafiltracion.
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2938357A1 (en) * 2012-12-28 2015-11-04 Novo Nordisk A/S High temperature dead end antibody filtration
JP6427502B2 (ja) 2013-01-09 2018-11-21 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａの精製方法
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
KR102707370B1 (ko) 2014-05-13 2024-09-13 암겐 인코포레이티드 필터 및 여과 공정과 함께 사용하기 위한 공정 제어 시스템 및 방법
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
US10207225B2 (en) 2014-06-16 2019-02-19 Emd Millipore Corporation Single-pass filtration systems and processes
US10550148B2 (en) * 2014-06-16 2020-02-04 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
ES2742704T3 (es) 2014-06-25 2020-02-17 Emd Millipore Corp Elementos, módulos y sistemas de filtro compactos, enrollados en espiral
SG10202006102UA (en) 2014-08-29 2020-07-29 Emd Millipore Corp Processes For Filtering Liquids Using Single Pass Tangential Flow Filtration Systems AndTangential Flow Filtration Systems With Recirculation of Retentate
ES2926043T3 (es) 2014-08-29 2022-10-21 Emd Millipore Corp Sistemas de filtración de flujo tangencial de paso único y sistemas de filtración de flujo tangencial con recirculación de retenido
SG11201703152RA (en) 2014-10-23 2017-05-30 Amgen Inc Reducing viscosity of pharmaceutical formulations
DK3763384T3 (da) 2014-12-03 2024-09-23 Csl Behring Ag Farmaceuitisk produkt med øget stabilitet, omfattende immunoglobuliner
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
CA2999118C (en) * 2015-09-22 2022-06-14 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
CN109195691B (zh) 2016-06-09 2022-04-29 Emd密理博公司 径向路径过滤器元件及使用其的系统和方法
WO2018035116A1 (en) * 2016-08-16 2018-02-22 Genzyme Corporation Methods of processing a fluid including a recombinant therapeutic protein and use thereof
CA3031860A1 (en) * 2016-08-17 2018-02-22 Boehringer Ingelheim International Gmbh Process for the preparation of highly concentrated liquid formulations containing biomolecules
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
WO2019132418A1 (ko) * 2017-12-27 2019-07-04 ㈜셀트리온 투석 여과 방법
US20210163531A1 (en) * 2018-04-12 2021-06-03 Amgen Inc. Methods for making stable protein compositions
TWI846694B (zh) * 2018-05-04 2024-07-01 美商健臻公司 具有過濾系統的灌注式生物反應器
AU2019316575A1 (en) * 2018-08-10 2021-03-04 Amgen Inc. Method of preparing an antibody pharmaceutical formulation
JP7483679B2 (ja) * 2018-08-14 2024-05-15 ブリストル－マイヤーズ スクイブ カンパニー 改善されたタンパク質の回収
MX2021008985A (es) * 2019-01-28 2021-09-08 Amgen Inc Procedimiento de fabricacion continuo para la fabricacion de productos biologicos mediante integracion de procedimientos de principio activo y producto terminado.
ES2890803T3 (es) * 2019-07-31 2022-01-24 Catalent Uk Swindon Zydis Ltd Caudalímetro de densidad para el campo de dosificaciones de formulaciones farmacéuticas
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
KR20230080460A (ko) * 2020-10-05 2023-06-07 브리스톨-마이어스 스큅 컴퍼니 단백질을 농축시키는 방법
EP4243966A1 (en) 2020-11-23 2023-09-20 Abec, Inc. Filtration systems,components and methods
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
EP4482956A1 (en) 2022-02-25 2025-01-01 Amgen Inc. Methods of preparing high concentration liquid drug substances
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
WO2024012364A1 (en) * 2022-07-12 2024-01-18 Beigene Switzerland Gmbh Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df)
WO2024224337A1 (en) * 2023-04-25 2024-10-31 Enzene Biosciences Limited In line cleaning in place process for alternating tangential flow filter
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (pt) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IN161706B (pt) * 1983-10-05 1988-01-16 Solco Basel Ag
US4786501A (en) 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
AU4589397A (en) 1997-09-22 1999-04-12 Sepragen Corporation Sequential separation of whey proteins and formulations thereof
RU2140287C1 (ru) 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
AU6405899A (en) 1998-10-26 2000-05-15 Galagen, Inc. Soy and immunoglobulin compositions
UY26236A1 (es) 1999-07-07 2000-10-31 New Zeland Co Operative Dairy Metodos para obtener aislados de proteina y concentrados de calostro
DK1314437T3 (da) * 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
JP2005521640A (ja) * 2001-11-13 2005-07-21 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド／ＴＲＡＩＬ製剤
JP2005530845A (ja) * 2002-06-21 2005-10-13 アイデック ファーマシューティカルズ コーポレイション 抗体を濃縮するための緩衝化処方物およびその使用方法
ES2318183T3 (es) * 2002-11-01 2009-05-01 Bayer Healthcare Llc Procedimiento de concentracion de proteinas.
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
EP1601788A4 (en) * 2003-02-24 2006-11-15 Gtc Biotherapeutics Inc METHOD OF TANGENTIAL ELECTRIC FILTRATION AND DEVICE THEREFOR
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
KR20070009995A (ko) 2004-01-30 2007-01-19 수오멘 푸나이넨 리스티 베리팔베루 바이러스 안전성 면역글로불린을 제조하는 방법
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法
US11220362B2 (en) 2017-08-16 2022-01-11 O & M Halyard, Inc. Method and system for wrapping ties in a facemask manufacturing process

Also Published As

Publication number Publication date
EP2292636B9 (en) 2024-01-03
JP5426641B2 (ja) 2014-02-26
CN104961797B (zh) 2020-12-25
CN102911268A (zh) 2013-02-06
JP2012097086A (ja) 2012-05-24
LT4108259T (lt) 2024-04-10
CN101056885B (zh) 2015-08-26
MX342788B (es) 2016-10-12
ES2528541T3 (es) 2015-02-10
HUE067296T2 (hu) 2024-10-28
FI4104859T3 (fi) 2024-07-16
EP4104859B1 (en) 2024-04-17
ES2983099T3 (es) 2024-10-22
US10370456B2 (en) 2019-08-06
PE20060816A1 (es) 2006-09-02
PT4108259T (pt) 2024-03-07
EP2292636B1 (en) 2023-10-18
PT3805248T (pt) 2023-04-05
FI3805248T3 (fi) 2023-04-21
MX2007002812A (es) 2007-05-16
HK1215869A1 (zh) 2016-09-23
WO2006031560A3 (en) 2006-08-24
TW200612989A (en) 2006-05-01
MA28991B1 (fr) 2007-11-01
HUE065025T2 (hu) 2024-04-28
SI4104859T1 (sl) 2024-08-30
ES2942574T3 (es) 2023-06-02
SI1786830T1 (sl) 2015-03-31
EP2292636A2 (en) 2011-03-09
PL3805248T3 (pl) 2023-05-22
SI2292636T1 (sl) 2024-02-29
HUE061899T2 (hu) 2023-08-28
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
DK2292636T3 (da) 2024-01-15
NZ553239A (en) 2009-11-27
FI2292636T3 (fi) 2024-01-12
EP1786830B1 (en) 2014-11-12
ES2975166T3 (es) 2024-07-03
CA2577317C (en) 2016-04-26
PL2292636T3 (pl) 2024-03-11
CN101056885A (zh) 2007-10-17
EP2292636A3 (en) 2013-05-01
AU2005285243C1 (en) 2012-10-25
ZA200701626B (en) 2008-10-29
US20140370003A1 (en) 2014-12-18
PL1786830T3 (pl) 2015-05-29
KR20120135530A (ko) 2012-12-14
DK4108259T3 (da) 2024-03-11
PT2292636T (pt) 2024-01-09
US20210095050A1 (en) 2021-04-01
PT1786830E (pt) 2015-02-05
DK3805248T5 (da) 2023-04-24
WO2006031560A2 (en) 2006-03-23
LT3805248T (lt) 2023-04-25
MY150549A (en) 2014-01-30
KR20070109975A (ko) 2007-11-15
DK4104859T3 (da) 2024-07-08
EP4108259B1 (en) 2024-01-03
AR050641A1 (es) 2006-11-08
BRPI0515649B1 (pt) 2021-10-13
EP3805248A2 (en) 2021-04-14
GT200500254A (es) 2006-08-02
EP4108259A1 (en) 2022-12-28
IL216851A0 (en) 2012-01-31
SI4108259T1 (sl) 2024-04-30
US20060051347A1 (en) 2006-03-09
HUE067662T2 (hu) 2024-11-28
KR101528970B9 (ko) 2022-12-09
US20230074486A1 (en) 2023-03-09
CA2577317A1 (en) 2006-03-23
TNSN07069A1 (en) 2008-06-02
PL4108259T3 (pl) 2024-05-13
PT4104859T (pt) 2024-07-02
JP5210633B2 (ja) 2013-06-12
FI4108259T3 (fi) 2024-09-10
US20090214522A1 (en) 2009-08-27
NO20071432L (no) 2007-03-16
TWI372630B (en) 2012-09-21
ECSP077282A (es) 2007-03-29
LT4104859T (lt) 2024-07-10
JP2008512473A (ja) 2008-04-24
US11767370B2 (en) 2023-09-26
CN104961797A (zh) 2015-10-07
PL4104859T3 (pl) 2024-08-26
KR101528970B1 (ko) 2015-06-15
EP3805248A3 (en) 2021-07-14
SI3805248T1 (sl) 2023-05-31
EP3805248B1 (en) 2023-01-18
EP4104859A1 (en) 2022-12-21
DK1786830T3 (en) 2015-01-19
HK1101249A1 (en) 2007-10-12
IL181372A0 (en) 2007-07-04
IL181372A (en) 2012-01-31
AU2005285243A1 (en) 2006-03-23
NO333660B1 (no) 2013-08-05
BRPI0515649A (pt) 2008-07-29
US20070237762A1 (en) 2007-10-11
ES2968070T3 (es) 2024-05-07
MY162525A (en) 2017-06-15
SG177161A1 (en) 2012-01-30
RU2390524C2 (ru) 2010-05-27
EP1786830A2 (en) 2007-05-23
DK3805248T3 (da) 2023-04-03
AU2005285243B2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
BRPI0515649B8 (pt) Processo para preparação de composições de anticorpo monoclonal altamente concentradas
DE69938302D1 (de) Neisseria meningitidis antigene und zusammenstellungen
NO2017028I2 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
CY1116285T1 (el) Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα
DK2327719T3 (da) Hybrid- og tandemekspression af neisseria-proteiner
PT1969007E (pt) Composições e métodos para a produção de uma composição
PL2314623T3 (pl) Przeciwciała wiążące il-1 beta i ich fragmenty
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
BRPI0606687A2 (pt) composições nutracêuticas
EP4374913A3 (en) Novel human serum albumin mutant
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
CY1115969T1 (el) Διαδικασια για συμπυκνωση αντισωματων και θεραπευτικων προϊοντων αυτων
JOP20050124B1 (ar) عملية تركيز الاجسام المضادة والمنتجات العلاجية منها
EP1467207A4 (en) Screening method
TH79576A (th) กรรมวิธีในการรวมแอนติบอดี้และผลิตภัณฑ์ที่ใช้ในการรักษาโรคซึ่งได้จากกรรมวิธีดังกล่าว

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/09/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2649, QUANTO AO ENDERECO DO TITULAR